Loading…
← CockpitCompetitor Analysis › 300147.SZ Xiangxue Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Xiangxue Pharmaceutical Co., Ltd. Class A300147.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum leader 84
Mkt cap
$591M
US dollars, full cap
Free float
75%
of shares outstanding
$/day
$20.7M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-38.7 pp
WACC 7.0%
Hurdle
+63 pp
Req g minus delivered
Close · CNYCN¥6.30
1D+15.6%
1W-0.8%
1M+46.5%
3M-15.4%
6M-40.9%
YTD-30.8%
1Y-36.8%
ATR %9.4%
52w lowhigh43.9% off high

What Xiangxue Pharmaceutical does

Employees: 2,662

Xiangxue Pharmaceutical at a glance

Size Xiangxue Pharmaceutical (300147.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $591M, the 3288th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥6.30 on 18 Nov 2026.

Performance Over six months the shares fell 40.9%, against -26.6% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.

Growth Revenue grew 2.9% over the last twelve months (peer median -2.5%); the operating margin is -38.5% (peer median 4.4%).

Valuation It trades at 3.7× enterprise value to sales against a peer median of 3.1× (8th most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is -12%, so the hurdle is +63 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 38.7 points below its cost of capital (7.0% WACC).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 75300147.SZ 62
Six months, rebased to 100: Xiangxue Pharmaceutical against the median of its 20 peers (local-currency closes).

Xiangxue Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.51BCN¥1.59BCN¥1.85BCN¥2.29BCN¥2.18B
Revenue growth—-14%-19%+5%—
Gross profitCN¥499MCN¥327MCN¥339MCN¥685MCN¥448M
EBITDAn/aCN¥75.2M-CN¥873,910CN¥262MCN¥51.1M
Net income-CN¥1.45B-CN¥1.39B-CN¥859M-CN¥389M-CN¥530M
Free cash flowCN¥25.8MCN¥118M-CN¥16.8MCN¥208M-CN¥139M
Capital expenditureCN¥27.1MCN¥21.5MCN¥35.2MCN¥56.0MCN¥367M
Total debtCN¥1.39BCN¥4.02BCN¥3.77BCN¥3.79BCN¥3.67B

Quarterly statements and history in the cockpit →

Xiangxue Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%-25%0%+25%+50%IMMXCGEM60097660343930109621574743DBV22563613002940ORCHPHARMAALMS4105300147.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Xiangxue Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-50%0%+50%0×50×100×6009766034393010962157474322563613603567ALMS300147.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Xiangxue Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%6009766034393002333613002793603567002940300194300147.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Xiangxue Pharmaceutical is the large dot.

Xiangxue Pharmaceutical competitors and peer comparison

How Xiangxue Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Xiangxue Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300147.SZPeer medianRank in peer set
1-month return+46.5%-11.8%highest of 20
6-month return-40.9%-26.6%5th lowest of 20
Distance from 52-week high-43.9%-44.1%10th highest of 20
Revenue growth (TTM)+2.9%-2.5%7th highest of 17
Operating margin-38.5%4.4%4th lowest of 16
EV / Sales3.7×3.1×8th most expensive of 17
Growth the price implies (Req g, 7 yrs)50.4%-0.8%most demanding of 11
Growth delivered (Del g)-12.3%+2.5%3rd lowest of 11
Hurdle (Req g minus delivered)+62.7 pp+0.0 ppmost demanding of 11
ROIC minus cost of capital-38.7 pp-3.9 pplowest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Xiangxue Pharmaceutical 300147.SZChina$591M-41%+3%-39%3.7×50.4%-12.3%
Immix Biopharma IMMXUnited States$596M-20%n/an/an/an/an/a
Cullinan Therapeutics CGEMUnited States$585M-37%n/an/an/an/an/a
JIANMIN PHARMACEUTICAL 600976.SSChina$598M-14%-2%8%0.9×-6.2%+6.5%
GuiZhou SanLi Pharmaceutical 603439.SSChina$583M-20%-6%5%2.6×20.9%+21.9%
Hangzhou Bio-Sincerity Pharma-Tech 301096.SZChina$602M-38%+5%-30%7.5×n/an/a
Lepu Biopharma 2157.HKHong Kong$580M-43%+47%7%4.5×n/an/a
Oneness Biotech 4743.TWOTaiwan$580M-13%+19%-589%101.5×n/an/a
Shandong Jincheng Pharmaceutical 300233.SZChina$604M-31%+2%4%1.2×-0.6%-1.6%
DBV Technologies DBV.PAFrance$604M-46%n/an/an/an/an/a
Abbisko Cayman 2256.HKHong Kong$578M-39%-83%-520%20.1×n/an/a
Beijing Tong Ren Tang Chinese Medicine 3613.HKHong Kong$577M-26%-21%32%1.9×-15.4%+2.8%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Alumis ALMSUnited States$569M-80%-67%-5,375%23.9×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%

Questions

Which companies are Xiangxue Pharmaceutical's closest peers?
The cockpit's peer set: Immix Biopharma (IMMX), Cullinan Therapeutics (CGEM), JIANMIN PHARMACEUTICAL (600976.SS), GuiZhou SanLi Pharmaceutical (603439.SS), Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ), Lepu Biopharma (2157.HK), Oneness Biotech (4743.TWO), Shandong Jincheng Pharmaceutical (300233.SZ).
Is Xiangxue Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.7× against a peer median of 3.1×, 8th most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 50% a year for seven years (Req g). Recent delivered growth is -12%, so the hurdle is +63 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Xiangxue Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -40.9% against -26.6% for the median peer; over one year -36.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.